janus kinase 1 (jak-1)

Atinvicitinib, a selective Janus kinase (JAK) inhibitor, demonstrates high specificity for Janus kinase 1 (JAK1), consequently inhibiting downstream cytokine signaling pathways that rely on JAK1 enzymatic activity. Atinvicitinib modulates a wide range of cytokines that are implicated in itch responses, allergic reactions, and inflammatory conditions, making it a significant research tool for studying cytokine-mediated immune processes as well as therapeutic modulation of allergic and inflammatory diseases.

Upadacitinib (ABT-494) (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM.

WHI-P154 (Jak3 inhibitor ii) is a potent JAK3 inhibitor.

JANEX-1 (Jak3 inhibitor I) is a cell-permeable, reversible, effective, ATP-competitive, and selective inhibitor of JAK3 (IC50: 78 μM); little inhibitory against JAK1/2, or Zap/Syk or SRC tyrosine kinases.

JAK-IN-36 (Compound 12e) is a potent and selective inhibitor of Janus Kinase 1 (JAK1), with an IC50 value of 2.2 nM. This compound is applicable for research in autoimmune diseases.

BRD0476 is a suppressor of pancreatic β-cell apoptosis. BRD0476 inhibits interferon-gamma (IFN-γ)-induced Janus kinase 2 (JAK2) and signal transducer and activation of transcription 1 (STAT1) signaling to promote β-cell survival. BRD0476 inhibits JAK-STAT

Ginsenoside Rk1 is a component created by processing the ginseng plant at high temperatures. Ginsenoside Rk1 has an anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB. It also has an anti-tumor effect.

TK4b can be used in the research of leukemia cancer and lymphoid-derived diseases. TK4b is a Janus kinase (JAK) inhibitor with the IC50 values of 18.42 nM and 19.40 nM for JAK3 and JAK2, respectively [1].

TK4g is a potent Janus kinase (JAK) inhibitor, demonstrating IC50 values of 12.61 nM and 15.80 nM against JAK2 and JAK3, respectively. It holds promise for research focused on lymphoid-derived diseases and leukemia cancer [1].

HAT-SIL-TG-1&AT, a hypoxia-activated prodrug, functions as a Janus tyrosine kinase (JAK) inhibitor demonstrating antitumor effects by inhibiting JAK-STAT signaling within tumor tissues. It also suppresses the proliferation of HEL cells and downregulates phosphorylated STAT3/5 in hypoxic conditions.

JAK-IN-26 (compound 2) is an orally active Janus kinase (JAK) inhibitor with favorable pharmacokinetic properties, demonstrating potency in suppressing IFN-α2B-induced STAT3 phosphorylation in Jurkat cells, with an IC50 value of 17.2 nM [1].

JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor with potential applicability in cancer and inflammatory disease research [1].

JAK-IN-30 (compound 31) is a water-soluble Janus kinase (JAK) inhibitor with IC50 values of 2 nM for JAK2, 15 nM for JAK1, 18 nM for JAK3, and 2 nM for TYK2, identified for its research potential in treating dry eye disease (DED) [1].

JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].

Protosappanin A (PTA) has anti-oxidative/nitrative activities on brain immune and neuroinflammation through regulation of CD14/TLR4-dependent IKK/IκB/NF-κB inflammation signal pathway; it exerts anti-neuroinflammatory effect by inhibiting JAK2-STAT3 pathway in lipopolysaccharide-induced BV2 microglia. Protosappanin A induces immunosuppression of rats heart transplantation targeting T cells in grafts via NF-kappaB pathway. Protosappanin A and protosappanin B have antimicrobial activity, they show both alone activities and resistance reversal effects of amikacin and gentamicin against MRSA. Protosappanin A shows strong effect against HIV-1 IN with an IC50 value of 12.6 uM.

Upadacitinib-15N-d2 the 15N and deuterated compound of Upadacitinib. Upadacitinib has a CAS number of 1310726-60-3. Upadacitinib (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM.